Last reviewed · How we verify
gefitinib and fulvestrant — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
gefitinib and fulvestrant (gefitinib and fulvestrant) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| gefitinib and fulvestrant TARGET | gefitinib and fulvestrant | AstraZeneca | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- gefitinib and fulvestrant CI watch — RSS
- gefitinib and fulvestrant CI watch — Atom
- gefitinib and fulvestrant CI watch — JSON
- gefitinib and fulvestrant alone — RSS
Cite this brief
Drug Landscape (2026). gefitinib and fulvestrant — Competitive Intelligence Brief. https://druglandscape.com/ci/gefitinib-and-fulvestrant. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab